Member Info for Saint68

Del - nice to see you back but I would have to disagree on your some of your opinions. The key word in the 1st sentence of CS response is "hopeful" - no mention of a promise, guarantee etc.

IMO nothings changed but the time frame. He's probably still in the same situation in not being able to tell us due to confidentiality so no point in repeating himself with pointless RNS stating the same.

Orhyblue - RNS' will only be released between 7am and 6.30pm UK time so the Yanks won't get any emails outside of those hours. That relates to 2am to 1.30pm New York time. Apologies if I've misread your email.

Think you mean the FDA oldslow65.

Great work Hulver - much appreciated. Nice to be reminded of the potential we have going forward.

FFS folks, please just green bin the dog. We knew he was a twat the day he turned up and you’re all just giving him air.

Tilly - a bit premature on winning the RNS comp as that was to do with the CH being lifted. This is a nice little bonus but those that have guesses for next week are still in the game :-)

EFM - For a definitive answer probably best to email the company as you'll probably get a few different responses here.

I am of the same opinion Haywain and have been a holder in both companies for roughly 4 years. I see a good outcome for both and hopefully my ticket for early retirement :-)

Haywain - in regards to Avact you're correct in saying that a targeted version of Doxorubicin is their lead candidate but that's not quite the whole story. It's the Precision platform that has the potential to be the golden goose there. It could potentially be used with any cytotoxic drug including the more advanced ADC therapies - much more potent. If the platform is as good as we think then in the words of our recently appointed head of R+D :

"The pipeline of cancer therapies at Avacta represents the next frontier in oncology innovation and includes the potential to help patients across multiple diseases, leveraging the tumour microenvironment as a target. I am thrilled to join the team during such a pivotal time for the company as we move our game-changing pipeline forward for the benefit of patients."

I agree with HH on this - if we don’t get news within the 30 day timeframe then that is the time to worry. This week would be a bonus but I’m not banking on it.

Missing bits :

11) If EUA2 is an option, then what industry will it be involved in and what operations will it be performing?

A: It is premature for us to discuss this while the sale process is our main priority.

12) Are you able to make any comment on the share price?

A: Not at this moment of time.

13) In the latest RNS mentions unsold inventories from 2022, does this include inventories from 2023 as well? Are these inventories unsold due to the war?

A: No mining took place in 2023, as previously notified.

14) It has been reported that Kovinsky Kamen are advertising for personnel to work at the WK site. It has also been noted by satellite that some work, clearing? is being carried out.

A: As previously announced, the site is operating on care and maintenance in advance of a possible sale. Should a buyer emerge, it will be easy to gear up for production with a new owner, thanks to the ongoing work at the site.

Below are answers to questions submitted by the telegram group :

1) Have both the Russian & HK counterparties completed their DD satisfactorily?

A: We draw investors’ attention to the latest update on the possible sale in the announcement of 7 December 2023. Further announcements will be made in accordance with regulatory obligations.

2) Can the BoD confirm if the concentrate is the whole production from WK or EUA’s 68% share and what’s the current net value to EUA

A: 100% as the other shareholders have not contributed to the capital investment.

3) Are any of the £1.65m of provisions made to the mineral extraction tax are now available as funds for EUA going forward?

A: The figure as announced was the first payment – further payments are expected to follow this year and announcements will be made as appropriate.

4) What is the “current” available cash for each of EUAs subsidiaries.

A: Please refer to the latest annual report on the Company website for the breakdown of the most recently published cash position of EUA’s subsidiaries. Updates regarding the Company’s cash position will be made via RNS.

5) How much more VAT credits are EUA expecting to receive.

A: Recovery of VAT is an ongoing process.

6) What is delaying the asset sales

A: The Company will continue to meet its regulatory obligations regarding updates to the market, including with respect to the possible sale of its assets. The Company will provide any material updates via RNS announcements following its obligations under the AIM Rules and MAR.

7) What is the delay with publishing the MT DFS.

A: As stated in the 7 December 2023 RNS, the Company is in a position where no further work will happen on the Monchetundra project as it is focused on the sale of assets. If those circumstances change, the Company will reassess its position to provide the whole of the market with the latest information. The payment, made in a previous announcement was made to keep us in good standing with our agreement.

8) Is there a cut-off point/date where the BOD are going to accept the Asset sale isn’t going to proceed and the better option for shareholders in the long term would be to activate the SinoSteel agreement.

A: While discussions continue with counterparties no alternative plans have been made.

9) Can you also ask Christian what the remuneration committee proposed salaries for 2024 for the Board of Directors and Senior Management 2024?

A: Please refer to the latest annual report on the Company website for the breakdown of remuneration.

10) Could you please confirm that EUA2 is still an option being

actively considered by the BOD or is the intention to wind up the

company after the sale of Russian assets?

A: The Company continues to keep this option alive pending a successful completion of the sale process.

11) If EUA2 is an option, then what industry will it be involved in and what operations will it be performing?

A: It is premature for us to discu

Sell up everybody - Trendz obviously knows more than our BOD who have told us money won’t be an issue. Nobody will engage with you because you’re talking rubbish. Do some more research ffs.

It was earlier and I took advantage 😁

The missing word is C1_1NT - in case you were wondering.

yes i have the balls and my opinion of you is that you’re a *******. been here 2 minutes and can’t stop posting. in the bin with the rest of the twats.

What for ? - I never criticised you in any way.

Dog - I assume you’ll be apologising to Bobby if he’s proved to be correct tomorrow ?

Phase 1 trials vary in length and some go on much longer than 1 year. Avacta for example are coming up to 3 years in their phase 1 for AVA6000. Hopefully it’ll much shorter than that here.

Cyrox - VAL saw a massive increase to their Mcap between March 2020 (600k) and September 2021 (26.6m). This was down to going clinical and making good progress through phase 1/2. They are now back at 7m due to some bad news along the way.